Mechanistically, PARPis enhance the level of PD-L1 expression on EMT6 tumor cells, a TNBC cell line, by inactivating the GSK3β pathway in vitro and in vivo, when inoculated into a syngeneic mouse model. The gene discussed is CD274; the disease is neoplasm.